building scalable therapeutics platform with mitochondrial genome editors
Spun out of Harvard and MIT in 2020, MitoLab is leveraging the founding team's broad domain expertise in DNA writing & genome engineering, synthetic gene circuit design, and bacterial & viral engineering to build a scalable platform for mitochondrial genome engineering.
Using our technology, we can enable mitochondrial genome editing to address mitochondrial genetic diseases.
There are at least 93 mitochondrial genetic disorders affecting 1 in 5000 people. All of these are incurable at the moment; they often lead to death or permanent disabilities (e.g., blindness, muscle atrophy). Current Standard of Care is limited to treatments that are highly ineffective or still in development.